Burlina Alessandro, Ardissone Anna, Battini Roberta, Burlina Alberto, Gasperini Serena, Pession Andrea, Porta Francesco, Vici Carlo Dionisi
Dept. of Medicine, Neurology Unit, St. Bassiano Hospital, Via dei Lotti 40, 36061, Bassano del Grappa, Italy.
Child Neurology Unit, Department of Pediatric Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
Neurol Sci. 2025 Apr 16. doi: 10.1007/s10072-025-08153-3.
Arginase 1 deficiency (ARG1-D) is a rare hereditary urea cycle disorder characterized by elevated arginine levels, resulting in progressive neurological impairment and severe physical and cognitive disability. Due to its low prevalence, overlapping symptoms with other neurological disorders, and current limitations in newborn screening tools, ARG1-D is often misdiagnosed or diagnosed late, limiting access to early interventions.
This review and expert opinion aim to provide an overview of the clinical manifestations, diagnostic challenges, and treatment options for ARG1-D, offering a practical resource for specialists to recognize this rare, progressive, yet treatable disease.
ARG1-D typically presents with progressive spastic paraplegia, developmental delays, cognitive impairment, and seizures, with symptom onset and severity varying by age. Differential diagnoses mainly include hereditary spastic paraplegia, cerebral palsy, and hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, each with distinct clinical features and biochemical markers. Potential red flags for ARG1-D include elevated plasma arginine levels, spasticity, seizures, and cognitive impairment. These should prompt further examinations to confirm the diagnosis, which is based on biochemical assays for hyperargininemia and on genetic testing. Once confirmed, early treatment is advised, including dietary protein restriction, ammonia scavengers, antiepileptic drugs, and novel therapies, such as pegzilarginase, which targets the disease's metabolic root.
Experts stress the importance of increased awareness of ARG1-D characteristics, noting that early recognition and treatment are crucial to patient outcomes. Greater recognition of ARG1-D's distinctive features, differential diagnosis, and diagnostic tools, even among non-specialist clinicians, could help prevent misdiagnoses and facilitate the identification of this rare yet treatable condition.
精氨酸酶1缺乏症(ARG1-D)是一种罕见的遗传性尿素循环障碍,其特征是精氨酸水平升高,导致进行性神经功能损害以及严重的身体和认知残疾。由于其发病率低、与其他神经系统疾病症状重叠,以及目前新生儿筛查工具的局限性,ARG1-D常被误诊或诊断较晚,从而限制了早期干预的机会。
本综述及专家意见旨在概述ARG1-D的临床表现、诊断挑战和治疗选择,为专科医生认识这种罕见、进行性但可治疗的疾病提供实用资源。
ARG1-D通常表现为进行性痉挛性截瘫、发育迟缓、认知障碍和癫痫发作,症状的发作和严重程度因年龄而异。鉴别诊断主要包括遗传性痉挛性截瘫、脑瘫和高鸟氨酸血症-高氨血症-高瓜氨酸尿症综合征,每种疾病都有独特的临床特征和生化标志物。ARG1-D的潜在警示信号包括血浆精氨酸水平升高、痉挛、癫痫发作和认知障碍。这些应促使进一步检查以确诊,诊断基于高精氨酸血症的生化检测和基因检测。一旦确诊,建议尽早治疗,包括饮食蛋白质限制、氨清除剂、抗癫痫药物以及新型疗法,如靶向该疾病代谢根源的聚乙二醇化精氨酸酶。
专家强调提高对ARG1-D特征认识的重要性,指出早期识别和治疗对患者预后至关重要。即使在非专科临床医生中,对ARG1-D独特特征、鉴别诊断和诊断工具的更多认识也有助于预防误诊,并促进对这种罕见但可治疗疾病的识别。